Please use a PC Browser to access Register-Tadawul
Get It
Eli Lilly's TOGETHER-PsO Open-label Phase 3B Trial Of Concomitant Use Of Taltz (Ixekizumab) And Zepbound (Tirzepatide) Compared To Taltz Alone For Moderate-to-severe Plaque Psoriasis And Obesity Met The Primary And All Key Secondary Endpoints
Eli Lilly and Company LLY | 1008.39 1003.00 | +1.82% -0.53% Pre |
